A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab

Inclusion criteria

• Adult participants aged ≥18 and ≤75 years.
• Diagnosis of moderate-to-severe HS (International Hidradenitis Suppurativa Severity Score System [IHS4] ≥4).
• Taking or planning to take secukinumab according to standard of care.
• Participants eligible for coronary imaging by Photon-Counting Computed Tomography (PCCT) based on at least one of the following:

• Evidence of coronary atherosclerotic plaque previously identified by imaging and receipt of stable, guideline-directed medical therapy.
• Clinical indication as determined by a cardiologist.
• Very high risk of developing cardiovascular diseases according to the Systematic Coronary Risk Evaluation 2 (SCORE2) and Systematic Coronary Risk Evaluation 2 - Older Persons (SCORE2-OP) risk models for moderate risk European regions (score ≥7.5% for participants <50 years old, score ≥10% for participants 50-69 years old, and score ≥15% for participants ≥70 years old).
• Signed Informed Consent Form (ICF), obtained from the participant or a legally authorized representative, prior to any study-related activities.

Exclusion criteria

• Known history of previous Myocardial Infarction (MI), Acute Coronary Syndromes (ACS) or Transient Ischemic Attack (TIA) requiring urgent intervention/hospitalization in the last 6 months prior to enrollment.
• Use of investigational cardiovascular or anti-inflammatory drugs.
• Use of any other investigational drugs.
• Chronic Kidney Disease (estimated Glomerular Filtration Rate [eGFR] <30 mL/min).
• Contraindications to perform PCCT (including allergies to contrast).
• Other autoimmune systemic diseases or active neoplastic diseases.
• Known history of Moderate to severe anemia.
• Congestive Heart Failure (New York Heart Association [NYHA] Class III-IV).
• Pregnant or lactating women.